Background: No previous studies exist examining two inhaled epoprosternol formulations (Flolan compared with Veletri) in a homogenous cardiothoracic surgery patient population.
Objective: To compare the impact of inhaled Flolan and inhaled Veletri on the effectiveness, safety, or cost in cardiothoracic surgery patients.
Materials And Methods: This was a retrospective, noninferiority study comparing inhaled Flolan and inhaled Veletri in cardiothoracic surgery patients. Participants included were ≥18 years old, admitted to the cardiothoracic intensive care unit, and received inhaled Flolan or inhaled Veletri therapy for ≥1 hour.
Results: A total of 244 patients were included in the primary outcome analysis (122 patients per group). The primary outcome, change in the partial pressure of arterial oxygen to fraction of inspired oxygen (PaO/FiO) ratio 1 hour after administration of inhaled Flolan or inhaled Veletri, did not cross the lower limit of the noninferiority margin (95% CI = -14.8 to 65.4). Significant differences in secondary outcomes included duration of mechanical ventilation (4.4 vs 2.6 days; P < 0.01), number of tracheostomies (24 vs 9; P = 0.01), number of patients initiated on dialysis (25 vs 12; P = 0.02), and cost per median duration of therapy ($257 vs $183; P = 0.02) in the inhaled Flolan and inhaled Veletri groups, with the average duration of therapy being 1.6 and 1.3 days, respectively.
Conclusions And Relevance: Inhaled Veletri was demonstrated to be non-inferior to inhaled Flolan when comparing change in PaO/FiO ratio 1 hour post -therapy initiation,and inhaled Veletri was an acceptable alternative to inhaled Flolan in a cardiothoracic surgery patient population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1060028018776432 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhaled epoprostenol via high-flow nasal cannula and intravenous treprostinil for management of severe pulmonary arterial hypertension during cesarean delivery with epidural anesthesia: a case report.
Int J Obstet Anesth
November 2024
TEAMHealth Anesthesia, United States; University of South Florida Department of Anesthesiology and Perioperative Medicine, United States. Electronic address:
Current guidelines for managing pulmonary arterial hypertension (PAH) in pregnancy recommend the use of PAH-specific medications, including phosphodiesterase type-5 inhibitors, calcium channel blockers, and prostacyclin analogs. However, there is limited consensus on the optimal agents and routes of administration during delivery. This case report describes a 24-year-old gravida 3 para 1 with Group I PAH, admitted at 29 weeks' gestation, for a planned cesarean delivery at 30 weeks gestation.
View Article and Find Full Text PDFEfficacy and determinants of response to inhaled treprostinil in pulmonary hypertension - interstitial lung disease.
Respir Med
November 2024
Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, OH, United States.
Inhaled treprostinil has shown to improve exercise capacity in patients with pulmonary hypertension-interstitial lung disease (PH-ILD). We evaluated the efficacy and determinants of favorable response to inhaled treprostinil at six months. METHODS: Of the 106 patients screened, 42 were eligible for this retrospective single-center study.
View Article and Find Full Text PDFPharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants.
Cardiol Young
October 2024
Children's Intensive Care Unit, KK Women's and Children's Hospital, Singapore, Singapore.
Background: New drugs to target different pathways in pulmonary hypertension has resulted in increased combination therapy, but details of this use in infants are not well described. In this large multicenter database study, we describe the pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants.
Methods: We identified inborn infants discharged home from a Pediatrix neonatal ICU from 1997 to 2020 exposed to inhaled nitric oxide, sildenafil, epoprostenol, or bosentan for greater than two consecutive days.
The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure.
Eur J Med Res
October 2024
Department of Pediatric Intensive Care Unit, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, People's Republic of China.
Article Synopsis
- The study investigated the effects of different administration regimens of intravenous treprostinil, a medication used in high-risk pediatric patients who underwent total cavo-pulmonary connection (TCPC) surgery, to improve postoperative recovery.
- It included a retrospective analysis of 51 pediatric patients divided into two groups based on the timing and dosing of treprostinil: Group 1 (earlier administration) and Group 2 (within one day post-surgery).
- Results showed comparable reductions in mean pulmonary arterial pressure (mPAP) after treatment in both groups, indicating that the timing of treprostinil administration may not significantly impact early postoperative outcomes.
The Influence of Pulmonary Arterial Hypertension In Pregnancy: A Review.
Cardiol Rev
September 2024
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Pulmonary arterial hypertension (PAH) is a severe condition characterized by increased pulmonary vascular resistance and right ventricular failure. This review examines the intersection of PAH and pregnancy, highlighting the significant physiological, hemodynamic, and hormonal changes that exacerbate PAH during gestation. Pregnancy is contraindicated in PAH patients due to high maternal and fetal morbidity and mortality rates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!